Chimerix (NASDAQ:CMRX) Share Price Passes Below 200-Day Moving Average of $0.96

Chimerix, Inc. (NASDAQ:CMRX)’s share price crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.96 and traded as low as $0.86. Chimerix shares last traded at $0.86, with a volume of 86,431 shares changing hands.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $11.00 price objective on shares of Chimerix in a research note on Wednesday, August 14th. StockNews.com upgraded shares of Chimerix from a “sell” rating to a “hold” rating in a research note on Wednesday, August 21st. Finally, Wedbush reiterated an “outperform” rating and set a $6.00 price objective on shares of Chimerix in a research note on Tuesday, August 13th.

Chimerix Stock Down 1.7 %

The firm has a market capitalization of $76.64 million, a PE ratio of -0.92 and a beta of 1.12. The firm’s 50 day moving average price is $0.90 and its two-hundred day moving average price is $0.96.

Chimerix (NASDAQ:CMRX) last announced its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, meeting the consensus estimate of ($0.23). The business had revenue of $0.13 million during the quarter, compared to the consensus estimate of $1.26 million. Chimerix had a negative net margin of 25,337.96% and a negative return on equity of 46.35%. During the same period in the prior year, the firm earned ($0.21) earnings per share. On average, sell-side analysts anticipate that Chimerix, Inc. will post -0.86 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in CMRX. Koshinski Asset Management Inc. bought a new position in Chimerix during the 1st quarter valued at $42,000. Marquette Asset Management LLC boosted its stake in Chimerix by 24.3% during the 1st quarter. Marquette Asset Management LLC now owns 116,009 shares of the biopharmaceutical company’s stock valued at $123,000 after acquiring an additional 22,709 shares during the last quarter. Marshall Wace LLP bought a new position in Chimerix during the 2nd quarter valued at $137,000. Pale Fire Capital SE boosted its stake in Chimerix by 113.6% during the 4th quarter. Pale Fire Capital SE now owns 211,214 shares of the biopharmaceutical company’s stock valued at $203,000 after acquiring an additional 112,318 shares during the last quarter. Finally, Vestal Point Capital LP bought a new position in shares of Chimerix in the 4th quarter worth about $1,348,000. 45.42% of the stock is currently owned by hedge funds and other institutional investors.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.